Good news for all of us supporting implementation of pharmacogenomics into clinical practise: EMA and BfArM recommend genetic testing before having a chemotherapy. More information: https://www.dgho.de/aktuelles/news/news/2020/positionspapier-zur-dpd-testung-veroeffentlicht
Doctors point to an increase in psychological health problems and psychiatric illnesses such as depression and anxiety related to the Sars-CoV-2 pandemic. Initial studies document this development, which experts believe may further intensify after the pandemic has subsided.
Psychopharmaceuticals are an important component of the therapy of mental illnesses. Many weeks and months often pass before the right medication and the appropriate dose have been determined for a patient.
What many do not know: Antidepressants in particular contain active substances, the effects of which are influenced by variants in genes, which can delay or even prevent successful therapy. With pharmacogenetic tests, it is possible to individually check whether and which variants a person has. With this knowledge, the doctor can adapt the active ingredient or the dosage to the personal genetic situation. The GIMS.pharma software system from bio.logis can be used to provide the wealth of information required for clinical use.
Euformatics partners with bio.logis to enable laboratories using its tertiary analysis platform to provide patients with pharmacogenomic dosing recommendations
Save the date: Learn more about upcoming congresses, where you can meet bio.logis and talk to our team ...
Read full article on medinside, published Oct 20th.
Medicines do not have the same effect on all patients. Because many factors affect drug response, physicians must select a drug that is appropriate for each individual and carefully adjust the dose. What many do not know and therefore often not considered in drug therapy: variants of DNA can lead to unwanted or insufficient drug effects (ADR). Get the whole story ....
The American AMP is responding with a position paper to the FDA-evoked discussions around PGx with clear recommendations on gene drug targets, laboratory and delivery of information for the POC.
Article on genomeweb
Association for Molecular Pathology Position Statement
The FDA's attention and UHC coverage indicate that PGx testing is finally coming to the standard care - in the US ...
Read free article on genomeweb.
by Daniela Steinberger
Genetisch bedingte Varianten von Proteinen des Medikamentenstoffwechsels können zu unerwünschten oder unzureichenden Arzneimittelwirkungen (UAW) führen.
Patient Empowerment/Förderung von E-Health Literacy/Shared Decision Making/digitale Patientenakten und Datenhoheit
Hier geht es zum vollständigen Artikel von Heike E. Krüger-Brand im Deutschen Ärzteblatt (Dtsch Arztebl 2019; 116(10): A-468 / B-382 / C-378).